Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company specializing in chronic low back pain diagnostics, announced on May 6, 2026, that its compensation committee granted an inducement stock option to Daniel Keefe, the company's recently appointed Commercial Director for the Western United States. The option to purchase 17,000 shares of common stock at an exercise price of $3.20 per share was granted on May 5, 2026, as a material inducement for Keefe to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option vests over a four-year period, with one-fourth vesting on the one-year anniversary of the vesting commencement date and the remainder vesting in equal monthly installments over the subsequent three years, contingent on Keefe's continued employment. The option carries a 10-year term. This grant underscores Aclarion's commitment to expanding its commercial presence in the Western U.S., a strategic move supported by triple-digit growth in utilization of its Nociscan platform.
Nociscan is a SaaS platform that noninvasively helps physicians identify painful versus nonpainful discs in the lumbar spine by leveraging magnetic resonance spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence algorithms. The platform receives MRS data from MRI machines via cloud connection, extracts and quantifies biomarkers associated with disc pain, and provides insights to optimize treatment strategies. According to the company, the expansion of the commercial team reflects increasing demand for Nociscan.
Aclarion's focus on chronic low back pain addresses a significant market need, as the condition affects millions worldwide and often leads to ineffective treatments due to difficulty in pinpointing pain sources. By providing evidence-supported, noninvasive diagnostic information, Nociscan aims to improve treatment success rates. For more information about Aclarion and Nociscan, visit www.aclarion.com.
This inducement grant and the broader commercial expansion highlight Aclarion's efforts to scale its sales force in response to growing adoption of its technology. The company's forward-looking statements caution that actual results may differ due to risks detailed in its filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025. Aclarion undertakes no obligation to update forward-looking statements.
